https://www.businesswire.com/news/home/20221031005225/en/Verge-Genomics-Initiates-First-In-Human-Dosing-in-Phase-1-Trial-of-VRG50635-a-Novel-Therapeutic-for-Amyotrophic-Lateral-Sclerosis
0
0
10/31/22 at 10:30am
Organization
Business Wire
Authors
Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform dr
Create an account
or login to join the discussion